Is there a role for surgery in recurrent gastric cancer

Annals of Surgical Oncology

Volumn 16, Issue 4, 2009, Pages 1074-1075

  Bali, C ^a   Ziogas, D ^a   Fatouros, E ^a   Fatouros, M ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; ESOPHAGUS CANCER; GASTRECTOMY; GENE EXPRESSION PROFILING; HUMAN; LETTER; PERIOPERATIVE PERIOD; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; SOLID TUMOR; STOMACH CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE;

HUMANS; JAPAN; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; STOMACH NEOPLASMS; WESTERN WORLD;

EID: 62349091113     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-008-0302-7     Document Type: Letter

References (26)

1. JA Ajani 2008 Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction: evolution of the docetaxel, cisplatin, and 5-fluorouracil regimen Cancer. 113 5 945 955 Review
2. DH Roukos AM Kappas 2005 Perspectives in the treatment of gastric cancer Nat Clin Pract Oncol. 2 98 107
3. DH Roukos 1999 Current advances and changes in treatment strategy may improve survival and quality of life in patients with potentially curable gastric cancer Ann Surg Oncol. 6 46 56
4. Badgwell B, Cormier JN, Xing Y, Yao J, Bose D, Krishnan S, et al. Attempted salvage resection for recurrent gastric or gastroesophageal cancer. Ann Surg Oncol. 2009;16(1):42-50.
5. DH Roukos 2004 Early-stage gastric cancer: a highly treatable disease Ann Surg Oncol. 11 127 129
6. DH Roukos C Hottenrott A Encke G Baltogiannis D Casioumis 1994 Primary gastric lymphomas: a clinicopathologic study with literature review Surg Oncol. 3 2 115 125
7. M Sasako T Sano S Yamamoto Y Kurokawa A Nashimoto A Kurita 2008 for Japan Clinical Oncology Group. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer N Engl J Med. 359 5 453 462
8. DH Roukos M Lorenz A Encke 1998 Evidence of survival benefit of extended (D2) lymphadenectomy in western patients with gastric cancer based on a new concept: a prospective long-term follow-up study Surgery. 123 5 573 578
9. AM Kappas DH Roukos 2002 Quality of surgery determinant for the outcome of patient with gastric cancer Ann Surg Oncol. 9 9 828 830
10. D Cunningham WH Allum SP Stenning JN Thompson CJ Van de Velde M Nicolson 2006 Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer N Engl J Med. 355 11 20
11. E Briasoulis M Fatouros DH Roukos 2007 Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol. 14 2691 2695
12. DH Roukos 2002 Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol. 9 220 221
13. E Briasoulis T Liakakos L Dova M Fatouros P Tsekeris DH Roukos 2006 Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer Expert Rev Anticancer Ther. 6 931 939
14. T Liakakos DH Roukos 2008 More controversy than ever - challenges and promises towards personalized treatment of gastric cancer Ann Surg Oncol. 15 4 956 960
15. DH Roukos 2008 Linking contralateral breast cancer with genetics Radiother Oncol. 86 139 141
16. M Fatouros G Baltoyiannis DH Roukos 2008 The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations Ann Surg Oncol. 15 1 21 33
17. DH Roukos AM Kappas NJ Agnantis 2003 Perspectives and risks of breast-conservation therapy for breast cancer Ann Surg Oncol. 10 718 721
18. M Fatouros DH Roukos I Arampatzis A Sotiriadis E Paraskevaidis AM Kappas 2005 Factors increasing local recurrence in breast-conserving surgery Expert Rev Anticancer Ther. 5 4 737 745
19. D Ziogas G Baltogiannis M Fatouros DH Roukos 2008 Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations Ann Surg. 247 4 714 715
20. DH Roukos 2007 Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations N Engl J Med. 357 15 1555 1556 author reply 1556.
21. Roukos DH. Breast-cancer stromal cells with TP53 mutations. N Engl J Med. 2008 10;358(15):1636; author reply 1636.
22. Roukos DH. Assessing both genetic variation (SNPs/CNVs) and gene-environment interactions may lead to personalized gastric cancer prevention. Expert Rev Mol Diagn. 2009;9(1):1-6.
23. DH Roukos E Lykoudis T Liakakos 2008 Genomics and challenges toward personalized breast cancer local control J Clin Oncol. 26 26 4360 4361
24. DH Roukos 2008 HER2 and response to paclitaxel in node-positive breast cancer N Engl J Med. 358 197 author reply 198
25. DH Roukos 2008 Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies Expert Rev Mol Diagn. 8 1 29 39
26. DH Roukos 2008 Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery Expert Rev Mol Diagn. 8 5 587 597